Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01600482 · ClinicalTrials.gov registry record · NA

Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)

A NA study of Coronary Artery Disease and Cardiac Disease, sponsored by Vasorum.

Completed
Registry status
NA
Development phase
241
Enrollment target
5
Study locations

NCT01600482: Completed NA study of Coronary Artery Disease and Cardiac Disease, sponsored by Vasorum.

NCT01600482 is a NA study of Coronary Artery Disease and Cardiac Disease that has completed, run by Vasorum. The registered enrollment target is 241 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01600482, a NA study of Coronary Artery Disease and Cardiac Disease, has completed, sponsored by Vasorum.

COMPLETED
Registry status
NA
Development phase
241 participants
Enrollment target
5
Study locations

Study Summary

The objective of the CELT ACD® Vascular Closure Device study is to evaluate the safety and effectiveness of the CELT ACD® device to achieve hemostasis of the common femoral artery access site in patients on anticoagulation who are undergoing a percutaneous intervention (PCI) procedure using a 6F sheath.

Primary Outcome

rate of major complications with in 30 +/- 7 days following the PCI procedure.

Interventions

  • DEVICE CELT ACD

Study Locations (5)

New Jersey

  • Cooper University Hospital - Camden

New York

  • New York Presbyterian Hospital - New York

Neuss

  • Städtische Kliniken Neuss - Lukaskrankenhaus - GmbH - Preußenstr. 84,41464 Neuss

Other

  • Charite Campus Mitte - Berlin

Ireland

  • Galway University Hosptial - Galway

Trial Details

FieldValue
Enrollment Target 241 participants
Start Date 2012-05
Est. Completion 2016-02
Phase NA
Vasorum

1 total trials

What the finished NCT01600482 record still lists

NCT01600482 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (81% lower).

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which CELT ACD is the first listed.

NCT01600482 lists 5 locations in 5 states (New Jersey, New York, Neuss).

Frequently Asked Questions

What is clinical trial NCT01600482 about?

NCT01600482 is a clinical study titled "Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)". The objective of the CELT ACD® Vascular Closure Device study is to evaluate the safety and effectiveness of the CELT ACD® device to achieve hemostasis of the common femoral artery access site in patients on anticoagulation who are undergoing a percutaneous intervention (PCI) procedure using a 6F she...

What is the current status of trial NCT01600482?

This trial is currently completed. It is a NA study. The enrollment target is 241 participants. The study started on 2012-05. Estimated completion is 2016-02.

What conditions does trial NCT01600482 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Cardiac Disease.

What interventions are being tested in trial NCT01600482?

The interventions under investigation include: CELT ACD (DEVICE).

Who is sponsoring clinical trial NCT01600482?

This trial is sponsored by Vasorum, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01600482 being conducted?

This trial has 5 study locations across New Jersey, New York, Neuss, Ireland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01600482's enrollment target sits among peer trials

241 112th of 219 higher than 108 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01189786 · 241 participants · NA

    Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

  • NCT05050383 · 241 participants · NA

    DISE: Phenotyping Obstruction Patterns

  • NCT05683418 · 241 participants · Phase 1

    A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors

  • NCT07213791 · 241 participants · Phase 1

    A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01600482, the US trial registry maintained by the National Library of Medicine. NCT01600482 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.